Recent Research
Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
-
New clinical practice guidelines for treating multiple myeloma
May 2019Mikhael J, et al., J Clin Oncol – A panel of experts convened by the American Society of Clinical Oncology and Cancer Care Ontario examined 124 published studies identified through a literature search on treating multiple myeloma to develop consensus, evidence-based recommendations for the treatment of patients who are transplant eligible and those who are ineligible and for patients with relapsed or refractory disease.
-
MRD-negative status prognostic for PFS and OS for patients with multiple myeloma
March 2019Hahn TE, et al., Bio Blood Marrow Transplant – Researchers found that minimal residual disease (MRD)-negative status may be a valuable addition with other clinical factors in determining further therapy needs for patients with multiple myeloma (MM). It can be prognostic for progression-free survival (PFS) and overall survival (OS) for patients with MM. -
Delayed Auto-HCT Can Lead to Inferior Survival Rates in Patients with MM
May 2018Kansagra A, et al. Biol Blood Marrow Transplant – Patients with multiple myeloma (MM) who undergo stem cell collection in preparation for an autologous HCT have lower outcomes if they delay transplant and are unable to receive their stem cells due to disease relapse. -
Allo-HCT Can Be an Effective Salvage Therapy for Multiple Myeloma
January 2018Montefusco V, et al. Bone Marrow Transplant – In this study of 71 patients with multiple myeloma undergoing hematopoietic cell transplantation (HCT), 5-year overall survival (OS) was 60%, with better outcomes in patients ≤55 years and in those transplanted with chemosensitive disease. -
Auto-HCT Can Be Safe for Myeloma Patients with Renal Insufficiency
November 2017Mahindra A, et al. Bone Marrow Transplant – In this study, researchers analyzed autologous hematopoietic cell transplantation (HCT) outcomes in 1,492 patients with multiple myeloma (MM) and renal insufficiency (RI). -
Cyclophosphamide Can Lower GVHD Rates in Patients with MM
August 2017Ghosh N, et al. Biol Blood Marrow Transplant – Allogeneic hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide can be safely performed in patients with multiple myeloma (MM), resulting in low rates of both acute and chronic graft-versus-host disease and rates of non-relapse mortality. -
Study Finds Disparity in HCT Utilization for Hispanics with Multiple Myeloma
June 2017Schriber JR, et al. Cancer – A study of 28,450 patients who underwent autologous HCT for multiple myeloma found that the rate of transplant utilization in the U.S. was significantly lower for Hispanic patients compared to non-Hispanic whites. The analysis also found that race/ethnicity did not affect post-transplant outcomes. -
Autologous HCT Plus RVD Therapy May Be Best for Patients with MM
May 2017Attal M, et al. N Engl J Med – A randomized trial of 700 patients with multiple myeloma (MM) has found that median progression-free survival is significantly longer in patients who underwent autologous HCT after combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) than in patients who received RVD alone: 50 months vs. 36 months, respectively (p<0.001). -
No Benefit of Additional Treatment After Auto-HCT for Myeloma with Lenalidomide Maintenance
December 2016Stadtmauer E, et al. ASH abstract oral presentation, December 2016 – The addition of consolidation therapy or a second autologous transplant is not superior to a single autologous transplant followed by lenalidomide maintenance in the upfront treatment of multiple myeloma, according to research presented at the Late-Breaking Abstracts session at ASH. -
Post-HCT Therapies May Improve Outcomes for Patients with High-Risk Myeloma
November 2016Scott EC, et al. Biol Blood Marrow Transplant – Therapies using bortezomib and immunomodulatory agents after autologous hematopoietic cell transplantation (HCT) for patients with high-risk (HR) multiple myeloma appears to contribute to improved HCT outcomes, with 3-year overall survival (OS) of 81%. -
In Era of Novel Agents, Autologous Transplant Still Preferred Treatment for Multiple Myeloma
August 2016Cavo M, et al. ASCO abstract oral presentation, June 2016 – Up-front autologous stem cell transplantation (ASCT) should remain the preferred treatment for younger patients who are newly diagnosed with multiple myeloma, according to results of a clinical trial reported at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. -
Review: Allogeneic HCT to Treat High-Risk Multiple Myeloma
January 2016Dhakal B, et al. Bone Marrow Transplant – In this review, the authors outline the use of allogeneic hematopoietic cell transplantation (HCT) to treat multiple myeloma (MM), noting that allogeneic HCT should be strongly considered only for high-risk MM patients as part of their initial course of therapy or in first chemotherapy-sensitive relapse within a clinical trial. -
Salvage Autologous Transplant Better than Non-Transplant Therapy in Relapsed Multiple Myeloma
December 2015Cook G, et al. ASH abstract oral presentation, December 2015 - A second autologous hematopoietic cell transplant (HCT) in multiple myeloma (MM) patients relapsing after a prior autologous HCT leads to better overall survival than non-transplant therapy, according to research presented at the ASH Annual Meeting. -
Autologous Transplantation for Multiple Myeloma in the Era of New Drugs
December 2015Attal M, et al. ASH abstract oral presentation, December 2015 - A multi-center randomized trial of 700 patients <65 years old with de novo multiple myeloma (MM) has shown that autologous hematopoietic cell transplantation (HCT) following treatment with lenalidomide, bortezomib and dexamethasone (RVD) is better than treatment with these drugs alone. -
Consensus Report: Salvage Therapy with HCT for Relapsed Multiple Myeloma
October 2015Giralt S, et al. Biol Blood Marrow Transplant – This consensus report from four professional transplant organizations establishes recommendations on the role of high-dose therapy with autologous or allogeneic HCT in multiple myeloma patients relapsing after primary therapy. -
Novel Agents for Consolidation and Maintenance Therapy After Auto-HCT for Multiple Myeloma
August 2015Mohty M, et al. Bone Marrow Transplant – Substantial improvements in the depth of response prior to transplant has been seen with the use of novel agents such as proteasome inhibitors and immunomodulatory drugs. -
Excellent Outcomes in Outpatient Autologous HCT for Patients with Myeloma or Lymphoma
July 2015Graff TM, et al. Bone Marrow Transplant – Researchers comparing outcomes of 230 patients with myeloma or lymphoma who underwent autologous hematopoietic cell transplantation (HCT) on an inpatient vs. outpatient basis within a single transplant program have found comparable outcomes in the two cohorts. -
ASBMT Evidence-Based Review: The Role of HCT in Multiple Myeloma
June 2015Shah N, et al. Biol Blood Marrow Transplant — This systematic evidence-based review by the American Society for Blood and Marrow Transplantation (ASBMT) evaluated the role of hematopoietic cell transplantation (HCT) in the treatment of multiple myeloma. -
Favorable Overall Survival Results for Allogeneic HCT in Patients with Multiple Myeloma
July 2014Donato ML, et al. Biol Blood Marrow Transplant — In this prospective study of 57 patients with multiple myeloma, 26 underwent allogeneic HCT for consolidation after a response to their first autologous transplant, and 30 patients received an allogeneic HCT as salvage therapy. -
Lenalidomide Maintenance after HCT for High-Risk Multiple Myeloma
July 2014Alsina M, et al. Biol Blood Marrow Transplant — A multi-center study of 30 high-risk patients transplanted for multiple myeloma has demonstrated 18-month overall survival of 78% for patients who received post-transplant lenalidomide maintenance therapy. -
Significant Improvement in HCT Survival Over Time
June 2013Hahn T, et al. J Clin Oncol - Survival for patients undergoing allogeneic hematopoietic cell transplantation (HCT) has significantly improved over time, according to a study of 38,060 patients with hematologic malignancies transplanted between 1994 and 2005 and reported to CIBMTR (Center for International Blood and Marrow Transplant Research).
-
Graft-Versus-Tumor Effects in Advanced Malignancies
March 2013Storb R, et al. J Clin Oncol - A study of a minimal-intensity pre-transplant conditioning regimen consisting of low-dose total body irradiation with or without fludarabine has shown that it can induce strong graft-versus-tumor (GVT) effects leading to lasting remissions in 45% to 75% of patients.
-
Lenalidomide after Autologous HCT for Multiple Myeloma Improves Survival
May 2012McCarthy PL, et al. N Eng J Med — Lenalidomide maintenance therapy following autologous hematopoietic cell transplantation (HCT) results in a significantly longer time to disease progression and significantly improved overall survival among patients with multiple myeloma.